By following this link you'll go directly to the site map at the end of each page
IT (EN)
   Person in charge: Barbara Ensoli
You're in:
Highlights
List view

1document

HIV-1 Tat vaccine results of the phase II trial in South Africa

A phase II clinical trial conducted in South Africa has confirmed that the therapeutic Tat vaccine against HIV/AIDS can effectively improve the response to antiretroviral drugs in people living with HIV. The results are published today in the peer-review open access journal Retrovirology: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T-cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial
Retrovirology 2016
doi: 10.1186/s12977-016-0261-1
After embargo, article is available at journal website here: http://retrovirology.biomedcentral.com/articles/10.1186/s12977-016-0261-1

Published 06-08-2016 in Highlights , last update 06-08-2016 More...

Share: 

2documents

Improving the effect of HIV drugs by the use of a vaccine

A vaccine containing a protein necessary for virus replication can boost an HIV-infected patient’s immune system, according to clinical research published in the open access journal Retrovirology. This boost can result in increased effectiveness of antiretroviral drugs.

Published 06-25-2015 in Highlights , last update 06-25-2015 More...

Share: 

UNRAVELING THE MECHANISMS REQUIRED FOR HIV VACCINE PROTECTION

As published today in PLoS ONE, by binding the Envelope protein present on virus particles, HIV Tat forms a new virus entry complex that favours the infection of cells present at the portals of virus entry (i.e. dendritic cells, macrophages). These cells represent also key HIV reservoirs that ensure the persistence of HIV in the host even under an "effective" antiretroviral treatment. By binding Env, Tat renders ineffective anti-Env antibodies at blocking virus entry in target cells. Thus, both anti-Tat and anti-Env antibodies are required for efficient HIV neutralization and should be both present to block HIV acquisition and spreading, but also the persistent infection and residual disease which is still present under antiretroviral therapy.

"This finding...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

1document

BARBARA ENSOLI WAS APPOINTED AMONG THE NEW MEMBERS OF THE ERC

Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

3documents

LAUNCH OF THE PHASE I TRIAL OF THE SECOND GENERATION OF PREVENTIVE VACCINE AGAINST HIV INFECTION BASED ON THE ASSOCIATION OF TAT AND ENV PROTEINS OF HIV-1 IN HEALTHY ADULT VOLUNTEERS

The National Center of the Istituto Superiore di Sanità launches the first phase of clinical testing of preventive HIV vaccine (study ISS P-002) based on a vaccine that combines the Tat protein, which is already advanced to therapeutic phase II trials in Italy and South Africa, and the Env protein,supplied by Novartis as part of a collaboration in the AVIP European project .
Tat and Env proteins have already been tested individually in clinical trials in humans and both were found to be safe and well tolerated, while to date the combination of the two products has been evaluated only in animal models where it has proved to be safe, well tolerated and capable of preventing HIV infection. The new study ISS P-002, involves 3 prominent clinical...

Published 06-15-2011 in Highlights , last update 03-28-2014 More...

Share: 

Legal information


© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information

ISS Home

Informiamo i visitatori, in virtù della individuazione delle modalità semplificate per l'informativa e l'acquisizione del consenso per l'uso dei cookie - 8 maggio 2014 (Pubblicato sulla Gazzetta Ufficiale n. 126 del 3 giugno 2014), che questo sito utilizza direttamente solo cookie tecnici.[Ho letto]